US stocks appear poised for a lower opening in Tuesday's trading session, as investors eagerly await the upcoming earnings reports this week along with anticipated comments from Federal Reserve Bank of Philadelphia President Patrick Harker, scheduled for later this morning. The futures for the Dow Jones Industrial Average declined by 0.4%, while S&P 500 futures decreased by 0.5%, and Nasdaq futures saw a drop of 0.7%.
Investors are keenly watching Harker's speech at a fintech conference for any insights related to future monetary policy adjustments by the Federal Reserve. Furthermore, the American Petroleum Institute is set to unveil its weekly crude oil data, which measures petroleum demand across the United States, later this afternoon.
Oil prices are experiencing an upward trend, with front-month global benchmarks Brent crude and West Texas Intermediate crude rising by 0.5% and 0.7%, respectively. In the broader context of global markets, Japan's Nikkei witnessed a decline of 1.4%, Hong Kong's Hang Seng showed an increase of 0.1%, and China's Shanghai Composite saw a rise of 0.5%.
Meanwhile, in Europe's early afternoon trading session, the UK's FTSE 100 decreased by 0.5%, while Germany’s DAX and France’s CAC experienced declines of 0.3% and 0.4%, respectively. In the realm of equities, shares of Ensysce Biosciences ($ENSC) skyrocketed by 177% in Tuesday's premarket trading, building on a previous session's 16% gain.
Genprex ($GNPX) shares surged more than 123% after a remarkable jump of 260% on Monday. Shares of SRM Entertainment ($SRM) rose by 40%, contributing to a 3.6% increase from Monday. TC Biopharm ($TCBP) shares made a significant rebound, gaining 41% after recovering from a previous session's decline of 55%, driven by the announcement of a research collaboration with Dr.
Carlos Maluquer de Motes aimed at developing a treatment for monkeypox. Urgent.ly ($ULY) advanced by 34% following a modest 1.7% loss on Monday. On the downside, shares of GRI Bio ($GRI.US) plummeted 22% after revealing an agreement to exercise certain warrants at a reduced price of $1 per share. IN8bio's ($INAB) shares fell by 16% after an impressive 75% jump in the prior session.
DMC Global ($BOOM) saw a sharp decline of 23% after the company reduced its Q3 sales guidance and flagged a non-cash goodwill impairment charge of $142 million. Sensei Biotherapeutics ($SNSE) dropped by 19% following a remarkable 78% gain in the preceding session. Shares of urban-gro (UGRO) lost nearly 14%, offsetting the previous sessions' 12% growth..